The Europe acne medication market was valued at US$ 1.96 billion in 2022 and is expected to reach US$ 3.11 billion by 2030; it is estimated to register at a CAGR of 6.0% from 2023 to 2030.
By leveraging artificial intelligence (AI), machine learning algorithms, genetic testing, and other cutting-edge tools, healthcare providers can now analyze vast data to gain a better understanding of patient's unique skin conditions, genetic predispositions, lifestyle factors, and treatment responses. This personalized approach allows for the development of tailored treatment plans specifically designed to address each patient's individual needs.
In March 2021, Onegevity, a health intelligence firm and a subsidiary of Thorne HealthTech, teamed up with Unilever, one of the top manufacturers of beauty and personal care products worldwide, to enable a more personalized approach to acne intervention and treatment. The scientific collaboration is meant to investigate the potential of multi-omics, or the integration of different biological disciplines, to enable more individualized approaches to treating acne. The collaboration aims to create new diagnostic models that can unlock customized acne treatment plans by utilizing Onegevity's AI and machine learning capabilities that allow the evaluation of billions of biological characteristics affecting a person's health.
Personalized treatment plans help to optimize treatment efficacy by taking into account patients' specific characteristics and factors that may influence their response to acne medication. Based on such patient-specific data, healthcare providers can prescribe treatments that are more likely to be effective for that particular individual. This improves the chances of successfully treating acne and reduces the likelihood of side effects and adverse reactions, leading to better patient outcomes and increased satisfaction. Thus, integrating advanced technologies and data-driven approaches for designing personalized treatment plans creates significant opportunities for innovation, growth, and improved patient outcomes in the Europe acne medication market.
Formel Skin, a Berlin-based business that is a pioneer in dermatology telehealth, announced the completion of a US$ 32.35 (30) million series fundraising round in January 2022. The funding was led by Singular and Heal Capital and supported by Cherry Ventures, Heartcore Capital, and Vorwerk Ventures. With this funding, the company plans to undertake the long-term development and expansion of its remote skincare platform.
Individualized Treatment Programs Based on Cutting-Edge Technologies and Data-Driven Strategies Drive Europe Acne Medication Market
Adopting advanced technologies and data-driven approaches in the Europe acne medication market opens up new avenues for research and development. By collecting and analyzing patient data, researchers can gain valuable insights into the underlying causes of acne, identify patterns and trends in treatment responses, and discover new potential targets for therapeutic interventions. This can drive the development of novel medications, innovative treatment strategies, and more personalized skincare products tailored to the diverse needs of acne patients.By leveraging artificial intelligence (AI), machine learning algorithms, genetic testing, and other cutting-edge tools, healthcare providers can now analyze vast data to gain a better understanding of patient's unique skin conditions, genetic predispositions, lifestyle factors, and treatment responses. This personalized approach allows for the development of tailored treatment plans specifically designed to address each patient's individual needs.
In March 2021, Onegevity, a health intelligence firm and a subsidiary of Thorne HealthTech, teamed up with Unilever, one of the top manufacturers of beauty and personal care products worldwide, to enable a more personalized approach to acne intervention and treatment. The scientific collaboration is meant to investigate the potential of multi-omics, or the integration of different biological disciplines, to enable more individualized approaches to treating acne. The collaboration aims to create new diagnostic models that can unlock customized acne treatment plans by utilizing Onegevity's AI and machine learning capabilities that allow the evaluation of billions of biological characteristics affecting a person's health.
Personalized treatment plans help to optimize treatment efficacy by taking into account patients' specific characteristics and factors that may influence their response to acne medication. Based on such patient-specific data, healthcare providers can prescribe treatments that are more likely to be effective for that particular individual. This improves the chances of successfully treating acne and reduces the likelihood of side effects and adverse reactions, leading to better patient outcomes and increased satisfaction. Thus, integrating advanced technologies and data-driven approaches for designing personalized treatment plans creates significant opportunities for innovation, growth, and improved patient outcomes in the Europe acne medication market.
Europe Acne Medication Market Overview
Europe ranks second in the global acne medication market. It is further anticipated to register a significant CAGR during the forecast period. The acne medication market growth in the region is ascribed to the increasing prevalence of acne and the growing presence of major players. The research-based pharmaceutical industry can play a key role in supporting the acne medication market growth in Europe and ensuring its future competitiveness in the global economy.Formel Skin, a Berlin-based business that is a pioneer in dermatology telehealth, announced the completion of a US$ 32.35 (30) million series fundraising round in January 2022. The funding was led by Singular and Heal Capital and supported by Cherry Ventures, Heartcore Capital, and Vorwerk Ventures. With this funding, the company plans to undertake the long-term development and expansion of its remote skincare platform.
Europe Acne Medication Market Segmentation
- The Europe acne medication market is segmented based on therapeutic class, formulation, type, acne type, distribution channel, and country.
- Based on therapeutic class, the Europe acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held the largest share in 2022.
- In terms of formulation, the Europe acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held a larger largest share in 2022.
- By type, the Europe acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held a larger largest share in 2022.
- Based on acne type, the Europe acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held a larger share in 2022.
- In terms of distribution channel, the Europe acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held the largest share in 2022.
- Based on country, the Europe acne medication market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe acne medication market in 2022.
- Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Galderma SA, Pfizer Inc, GSK Plc, Viatris Inc, and Pierre Fabre SA are some of the leading companies operating in the Europe acne medication market.
Market Highlights
- Based on therapeutic class, the Europe acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held 33.6% share of the Europe acne medication market in 2022, amassing US$ 659.43 million. It is projected to garner US$ 1.14 billion by 2030 to expand at 7.2% CAGR during 2023-2030.
- In terms of formulation, the Europe acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held 68.5% share of the Europe acne medication market in 2022, amassing US$ 1.34 billion. It is estimated to garner US$ 2.20 billion by 2030 to expand at 6.4% CAGR during 2023-2030.
- The prescription medicine segment held 65.3% share of Europe acne medication market in 2022, amassing US$ 1.28 billion. It is predicted to garner US$ 2.09 billion by 2030 to expand at 6.4% CAGR during 2023-2030.
- The inflammatory acne segment held 54.6% share of the Europe acne medication market in 2022, amassing US$ 1.07 billion. It is projected to garner US$ 1.73 billion by 2030 to expand at 6.3% CAGR during 2023-2030.
- In terms of distribution channel, the Europe acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held 49.6% share of the Europe acne medication market in 2022, amassing US$ 974.65 million. It is estimated to garner US$ 1.63 billion by 2030 to expand at 6.7% CAGR during 2023-2030.
- Germany held 29.4% share of Europe acne medication market in 2022, amassing US$ 577.14 million. It is projected to garner US$ 997.62 million by 2030 to expand at 7.1% CAGR during 2023-2030.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe acne medication market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Europe acne medication market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Acne Medication Market Landscape
5. Europe Acne Medication Market - Key Market Dynamics
7. Europe Acne Medication Market Analysis - by Therapeutic Class
8. Europe Acne Medication Market Analysis - by Formulation
9. Europe Acne Medication Market Analysis - by Type
10. Europe Acne Medication Market Analysis - by Acne Type
11. Europe Acne Medication Market Analysis - by Distribution Channel
12. Europe Acne Medication Market - Country Analysis
13. Acne Medication Market- Industry Landscape
14. Company Profiles
15. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the Europe Acne Medication market include:- Teva Pharmaceutical Industries Ltd
- Almirall SA
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd
- Bausch Health Companies Inc
- Galderma SA
- Pfizer Inc
- GSK Plc
- Viatris Inc
- Pierre Fabre SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 127 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.96 Billion |
| Forecasted Market Value ( USD | $ 3.11 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 11 |
